Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients

Roxadustat (FG‐4592), an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, was evaluated in a phase 1b study in patients with end‐stage renal disease with anemia on hemodialysis. Seventeen patients, on epoetin‐alfa maintenance therapy with stable hemoglobin l...

Descripción completa

Detalles Bibliográficos
Autores principales: Provenzano, Robert, Tumlin, James, Zabaneh, Raja, Chou, James, Hemmerich, Stefan, Neff, Thomas B., Yu, K.‐H. Peony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586807/
https://www.ncbi.nlm.nih.gov/pubmed/32603526
http://dx.doi.org/10.1002/jcph.1648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586807/
https://www.ncbi.nlm.nih.gov/pubmed/32603526
http://dx.doi.org/10.1002/jcph.1648

Ejemplares similares